Xilio Therapeutics IncNASDAQ:XLO
- LAST PRICE1.0900
- TODAY'S CHANGE (%)0.0800 (7.9208%)
- Bid / Lots1.0500/ 3
- Ask / Lots1.1100/ 2
- Open / Previous Close1.0200 / 1.0100
- Day Range
- 52 Week Range
- Volume144,163
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XLO |
|---|---|---|
| 09:32 ET | 1795 | 1.08 |
| 09:34 ET | 112 | 1.0401 |
| 09:36 ET | 265 | 1.07 |
| 09:43 ET | 600 | 1.0595 |
| 09:45 ET | 700 | 1.08 |
| 09:48 ET | 222 | 1.06 |
| 09:56 ET | 2000 | 1.05 |
| 09:57 ET | 1200 | 1.06 |
| 10:01 ET | 500 | 1.09 |
| 10:08 ET | 1000 | 1.09 |
| 10:10 ET | 2600 | 1.06 |
| 10:14 ET | 427 | 1.06 |
| 10:24 ET | 1000 | 1.0589 |
| 10:26 ET | 2000 | 1.056 |
| 10:30 ET | 5212 | 1.06 |
| 10:35 ET | 100 | 1.08 |
| 10:39 ET | 100 | 1.09 |
| 10:42 ET | 10200 | 1.09 |
| 10:44 ET | 1000 | 1.09 |
| 10:46 ET | 5500 | 1.0504 |
| 10:48 ET | 100 | 1.09 |
| 10:51 ET | 100 | 1.09 |
| 10:53 ET | 100 | 1.09 |
| 10:55 ET | 100 | 1.09 |
| 10:57 ET | 9100 | 1.0999 |
| 11:00 ET | 300 | 1.09 |
| 11:04 ET | 100 | 1.1 |
| 11:06 ET | 100 | 1.09 |
| 11:08 ET | 100 | 1.09 |
| 11:09 ET | 9037 | 1.1 |
| 11:11 ET | 934 | 1.11 |
| 11:13 ET | 7661 | 1.09 |
| 11:15 ET | 1000 | 1.085 |
| 11:18 ET | 500 | 1.1 |
| 11:22 ET | 200 | 1.07 |
| 11:24 ET | 300 | 1.07 |
| 11:27 ET | 1200 | 1.09 |
| 11:29 ET | 500 | 1.1 |
| 11:31 ET | 700 | 1.08 |
| 11:33 ET | 400 | 1.08 |
| 11:36 ET | 450 | 1.09 |
| 11:40 ET | 600 | 1.09 |
| 11:42 ET | 100 | 1.07 |
| 11:44 ET | 1100 | 1.07 |
| 11:45 ET | 8042 | 1.1 |
| 11:49 ET | 100 | 1.1 |
| 11:51 ET | 200 | 1.08 |
| 11:54 ET | 700 | 1.085 |
| 11:56 ET | 200 | 1.1 |
| 11:58 ET | 100 | 1.1 |
| 12:02 ET | 400 | 1.08 |
| 12:03 ET | 200 | 1.07 |
| 12:05 ET | 100 | 1.09 |
| 12:07 ET | 100 | 1.09 |
| 12:12 ET | 500 | 1.07 |
| 12:14 ET | 100 | 1.07 |
| 12:18 ET | 100 | 1.08 |
| 12:21 ET | 100 | 1.07 |
| 12:23 ET | 497 | 1.0506 |
| 12:34 ET | 4200 | 1.06 |
| 12:39 ET | 12400 | 1.05 |
| 12:45 ET | 499 | 1.06 |
| 12:50 ET | 700 | 1.055 |
| 12:52 ET | 400 | 1.055 |
| 12:56 ET | 250 | 1.0501 |
| 12:57 ET | 100 | 1.06 |
| 12:59 ET | 794 | 1.06 |
| 01:01 ET | 100 | 1.06 |
| 01:06 ET | 100 | 1.06 |
| 01:10 ET | 2100 | 1.06 |
| 01:14 ET | 100 | 1.06 |
| 01:15 ET | 100 | 1.06 |
| 01:17 ET | 300 | 1.06 |
| 01:24 ET | 1174 | 1.06 |
| 01:26 ET | 100 | 1.07 |
| 01:35 ET | 100 | 1.06 |
| 01:44 ET | 200 | 1.06 |
| 01:46 ET | 100 | 1.07 |
| 01:48 ET | 100 | 1.07 |
| 02:00 ET | 800 | 1.065 |
| 02:02 ET | 100 | 1.065 |
| 02:20 ET | 2120 | 1.067 |
| 02:22 ET | 2441 | 1.07 |
| 02:26 ET | 300 | 1.08 |
| 02:27 ET | 2980 | 1.08 |
| 02:31 ET | 100 | 1.07 |
| 02:33 ET | 300 | 1.07 |
| 02:36 ET | 300 | 1.09 |
| 02:38 ET | 100 | 1.07 |
| 02:42 ET | 200 | 1.07 |
| 02:44 ET | 400 | 1.07 |
| 02:45 ET | 100 | 1.07 |
| 02:47 ET | 200 | 1.07 |
| 02:51 ET | 200 | 1.07 |
| 02:54 ET | 300 | 1.07 |
| 02:56 ET | 200 | 1.07 |
| 02:58 ET | 200 | 1.08 |
| 03:03 ET | 400 | 1.07 |
| 03:05 ET | 700 | 1.07 |
| 03:16 ET | 1000 | 1.07 |
| 03:36 ET | 100 | 1.07 |
| 03:39 ET | 100 | 1.07 |
| 03:41 ET | 600 | 1.0663 |
| 03:43 ET | 100 | 1.065 |
| 03:48 ET | 550 | 1.0602 |
| 03:56 ET | 200 | 1.08 |
| 03:57 ET | 8305 | 1.08 |
| 03:59 ET | 6890 | 1.09 |
Apr 1, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results, from 4:05PM ET on Monday Apr 01, 2024 by Dow Jones
4:05PM ET on Monday Apr 01, 2024 by Dow JonesPress Release: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results, from 4:05PM ET on Monday Apr 01, 2024 by Dow Jones
4:05PM ET on Monday Apr 01, 2024 by Dow JonesThinking about buying stock in RPM International, Xilio Therapeutics, KULR Technology, Torrid Holdings, or IGM Biosciences?, from 9:31AM ET on Monday Apr 01, 2024 by Dow Jones
9:31AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
DJ Xilio Shares Take Flight Premarket After Gilead Deal, from 9:20AM ET on Thursday Mar 28, 2024 by Dow Jones
9:20AM ET on Thursday Mar 28, 2024 by Dow JonesDJ Xilio Therapeutics Plans Private Placement, Job Cuts, from 7:32AM ET on Thursday Mar 28, 2024 by Dow Jones
7:32AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xilio Therapeutics Inc | 34.8M | -0.4x | --- |
Protara Therapeutics Inc | 34.9M | -0.8x | --- |
NextCure Inc | 36.0M | -0.6x | --- |
QSAM Biosciences Inc | 36.0M | -5.1x | --- |
Brainstorm Cell Therapeutics Inc | 36.4M | -1.3x | --- |
Viracta Therapeutics Inc | 33.3M | -0.6x | --- |
Company Information
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Contact Information
- Headquarters
- 828 Winter Street, Suite 300WALTHAM, MA, United States 02451
- Phone
- 617-430-4680
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Clancy
- President, Chief Executive Officer, Director
- Rene Russo
- Chief Operating Officer
- Christopher Frankenfield
- Senior Vice President - Finance & Accounting
- Kevin Brennan
- Chief Development Officer
- Scott Coleman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.78 |
Book Value | $1.33 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
